Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severityMads Delbo Larsen, Marianna Bugiani, Rogier W. Sanders et al.|Science|2020Cited by 415
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort studyMichela Botta, Liselotte Hol, Anissa M. Tsonas et al.|The Lancet Respiratory Medicine|2020Cited by 306
Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care MedicineAlexander P. J. Vlaar, Maurizio Cecconi, Simon Oczkowski et al.|Intensive Care Medicine|2020Cited by 279
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trialAlexander P. J. Vlaar, Diederik van de Beek, Sanne de Bruin et al.|The Lancet Rheumatology|2020Cited by 199
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialAlexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al.|The Lancet Respiratory Medicine|2022Cited by 143